Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2008 Jul 1;18(13):3695-700. doi: 10.1016/j.bmcl.2008.05.073. Epub 2008 May 22.

Novel benzimidazole derivatives as selective CB2 agonists.

Author information

1
Department of Medicinal Chemistry, AstraZeneca R&D Montréal, 7171 Frederick-Banting, St-Laurent, Que., Canada. daniel.page@astrazeneca.com

Erratum in

  • Bioorg Med Chem Lett. 2008 Sep 1;18(17):4914. Payza, Keymal [corrected to Payza, Kemal].

Abstract

The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.

PMID:
18522867
DOI:
10.1016/j.bmcl.2008.05.073
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center